05:31 , May 2, 2019 |  BC Extra  |  Company News

AstraZeneca adds oncolytic virus option through Transgene deal

AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene. On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
22:39 , Mar 29, 2019 |  BioCentury  |  Finance

ORI goes oncolytic

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer. ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold...
14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
16:39 , Mar 22, 2019 |  BC Week In Review  |  Financial News

Cold Genesys closes $22M series C

Cold Genesys raised $22 million in a series C round Monday to fund development of its lead immunotherapy, CG0070, which has completed Phase II testing to treat non-muscle invasive bladder cancer (NMIBC). Cold Genesys Inc....
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
21:16 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting GM-CSF in CAR Ts to prevent therapy-induced cytokine release syndrome

DISEASE CATEGORY: Inflammation INDICATION: Cytokine release syndrome (CRS) Cell culture studies suggest inhibiting GM-CSF produced by CAR T cells could help prevent CRS in lymphoma patients receiving CAR T therapies. In a co-culture assay in...
01:48 , Mar 1, 2019 |  BC Innovations  |  Translation in Brief

Targeting pathogenic Th17 cells

A recent pair of studies offers two new approaches to treating autoimmune diseases that go after the source of Th17-mediated inflammation. T helper type 17 (Th17) cells are effector T cells that secrete the cytokine...
13:02 , Feb 28, 2019 |  BC Extra  |  Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety. While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has...
13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest an oncolytic herpes simplex virus (HSV) expressing CDH1 could help treat glioblastoma multiforme (GBM). An oncolytic HSV was engineered to express human CDH1 to enhance cell-to-cell transmission and reduce...